ACC.24: TAVI Vs SAVR in Patients with Severe Aortic Valve Stenosis: DEDICATE-DZHK6

Published: 08 Apr 2024

  • Views:

    Views Icon 225
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

ACC.24 — Investigator Dr Moritz Seiffert (University Heart and Vascular Center Hamburg, DE) joins us onsite at ACC to discuss the findings of the DEDICATE-DZHK6 Trial (NCT03112980).

This randomized controlled, multi-center trial aimed to investigate whether transcatheter aortic valve implantation (TAVI) is non-inferior to surgical aortic valve replacement (SAVR) in patients with symptomatic severe aortic stenosis at low to intermediate operative risk of mortality, as measured by all-cause mortality or stroke at 1 and 5 years. 1414 patients were enrolled in this trial, and were randomized in a 1:1 fashion to receive either TAVI or SAVR.

Findings showed that, among patients with severe aortic stenosis at low or intermediate surgical risk, TAVI with prosthesis selection based on operator discretion was non-inferior to SAVR in regard to risk of death from any cause or stroke at 1 year.

Interview Questions:

  1. What is the importance of this study?
  2. What was the study design and patient population?
  3. What are the key findings?
  4. How should these findings impact clinical practice?
  5. What is the main take-home message?
  6. Where are the knowledge gaps?

Recorded remotely from Atlanta, 2024.

For more content from ACC.24 head to the Late-breaking Science Video Collection.


Support: This is an independent interview conducted by Radcliffe Cardiology.

Editors: Jordan Rance, Mirjam Boros

Video Specialists: Dan Brent, Tom Green, Mike Knight


You must be to comment. If you are not registered, you can register here.